Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Clin Lung Cancer. 2016 Jun 27;18(1):5–12. doi: 10.1016/j.cllc.2016.06.007

Figure 1.

Figure 1

ALCHEMIST Aims to Determine Survival Impact of Additional Targeted Therapy or Immunotherapy in Patients Who Have Undergone Resection and Standard Adjuvant Chemotherapy for Stage IB-IIIA Nonsquamous NSCLC. A081107 Investigates 2 Years of Erlotinib Versus Placebo in EGFR-Mutant NSCLC. EA4512 Compares Crizotinib Versus Placebo in ALK-Mutant NSCLC. EA5142 Randomizes Patients to Receive Either 1 Year of Nivolumab Versus Observation in PD-L1 Positive Patients Defined by >3% Staining by Immunohistochemistry

Abbreviation: NSCLC = non–small-cell lung cancer.